Pancreatic Cancer Research

ResearcherKindai University HospitalActive in the last 2 years

Masatoshi Kudo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4102-3474; OpenAlex author ID A5032900701, A5110483613. Sources: OpenAlex.

Their work

Papers
31 (first author 0, last author 21)
Trials
0
Grants
0
Labs led
2
Collaborators
50
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: 3 papers · 2019: 4 papers · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 31

  1. Response to the letter to the editor regarding "Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and ident… Last author DOI 10.1016/j.pan.2025.12.005↗
  2. Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients. Last author DOI 10.1016/j.pan.2025.02.013↗
  3. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  4. Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. Co-author DOI 10.1038/s41416-024-02794-5↗
  5. Early diagnosis of pancreatic cancer via pancreatic juice cytology with a cell-block method in a patient with altered anatomy Last author DOI 10.1055/a-2317-0520↗
  6. Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomiz… Last author DOI 10.1002/jgh3.12966↗
  7. Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy. Last author DOI 10.1007/s10147-023-02396-w↗
  8. Efficacy of EUS-guided celiac plexus neurolysis in combination with EUS-guided celiac ganglia neurolysis for pancreatic cancer-associated pain: a multicenter p… Co-author DOI 10.1007/s10147-022-02160-6↗
  9. Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. Last author DOI 10.4103/eus-d-21-00185↗
  10. Improved detection of liver metastasis using Kupffer-phase imaging in contrast-enhanced harmonic EUS in patients with pancreatic cancer (with video). Last author DOI 10.1016/j.gie.2020.06.051↗
  11. Value of Low-Mechanical-Index Contrast-Enhanced Transabdominal Ultrasound for Diagnosis of Pancreatic Cancer: A Meta-analysis. Co-author DOI 10.1016/j.ultrasmedbio.2021.08.005↗
  12. Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopancreatography Findings. Last author DOI 10.3390/diagnostics11101858↗
  13. Response to the Letter to the Editor 'Reply to "Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients T… Last author DOI 10.2169/internalmedicine.3958-19↗
  14. Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Loca… Last author DOI 10.3390/diagnostics10070445↗
  15. Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer. Last author DOI 10.1016/j.dld.2019.03.015↗
  16. Value of contrast-enhanced harmonic endoscopic ultrasonography with enhancement pattern for diagnosis of pancreatic cancer: A meta-analysis. Co-author DOI 10.1111/den.13290↗
  17. Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrosp… Last author DOI 10.2169/internalmedicine.2234-18↗
  18. Can Localized Stenosis of the Main Pancreatic Duct be a Predictive Factor for Early Detection of Pancreatic Cancer? Last author DOI 10.5946/ce.2019.204↗
  19. Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of FNA for pancreatic adenocarcinoma. Last author DOI 10.1016/j.gie.2017.05.052↗
  20. Outcomes of endoscopic biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: a multicenter cohort study in West Japan. Last author DOI 10.1016/j.gie.2018.01.021↗
  21. Alleviating Pancreatic Cancer-Associated Pain Using Endoscopic Ultrasound-Guided Neurolysis. Last author DOI 10.3390/cancers10020050↗
  22. Association between the Risk Factors for Pancreatic Ductal Adenocarcinoma and Those for Malignant Intraductal Papillary Mucinous Neoplasm. Last author DOI 10.1159/000481234↗
  23. EUS-Guided Pancreatic Duct Drainage for Repeat Pancreatitis in a Patient with Pancreatic Cancer. Last author DOI 10.1159/000481238↗
  24. A Social Program for the Early Detection of Pancreatic Cancer: The Kishiwada Katsuragi Project. Last author DOI 10.1159/000481239↗
  25. Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. Co-author DOI 10.3892/ijo.2017.3961↗
  26. Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancer. Last author DOI 10.1177/1756283x16644248↗
  27. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2014.10.037↗
  28. Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Co-author DOI 10.1186/1476-4598-13-126↗
  29. Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer. Co-author DOI 10.1093/jjco/hyr178↗
  30. The prognosis of patients with pancreatic cancer is extremely poor. Preface. Co-author DOI 10.1159/000323476↗
  31. Endoscopic ultrasound-guided neurolysis in pancreatic cancer. Last author DOI 10.1159/000323513↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kentaro Yamao · 18 shared papers, 2016–2026 · strength 2.37
  2. Mamoru Takenaka · 18 shared papers, 2017–2026 · strength 2.35
  3. Kosuke Minaga · 18 shared papers, 2016–2025 · strength 2.02
  4. Ken Kamata · 17 shared papers, 2011–2025 · strength 1.67
  5. Masayuki Kitano · 15 shared papers, 2011–2023 · strength 1.17
  6. Atsushi Nakai · 8 shared papers, 2017–2023 · strength 0.74
  7. Takuya Ishikawa · 2 shared papers, 2025–2026 · strength 0.57
  8. Yasuo Otsuka · 3 shared papers, 2022–2024 · strength 0.52
  9. Hidekazu Tanaka · 4 shared papers, 2019–2023 · strength 0.46
  10. Ippei Matsumoto · 5 shared papers, 2017–2022 · strength 0.45
  11. Yoshifumi Takeyama · 6 shared papers, 2012–2022 · strength 0.43
  12. Hiroki Kawashima · 1 shared paper, 2026 · strength 0.36
  13. Yukitaka Yamashita · 3 shared papers, 2018–2024 · strength 0.34
  14. Kazuto Nishio · 5 shared papers, 2012–2023 · strength 0.33
  15. Masakatsu Tsurusaki · 3 shared papers, 2020–2021 · strength 0.32
  16. Hiroki Sakamoto · 6 shared papers, 2011–2018 · strength 0.30
  17. Yasunobu Yamashita · 2 shared papers, 2019–2021 · strength 0.24
  18. Tadashi Iida · 1 shared paper, 2025 · strength 0.22
  19. Yasuyuki Mizutani · 1 shared paper, 2025 · strength 0.22
  20. Yoshihisa Takada · 1 shared paper, 2025 · strength 0.22
  21. Takeshi Ogura · 1 shared paper, 2022 · strength 0.15
  22. Yosuke Togashi · 3 shared papers, 2014–2017 · strength 0.14
  23. Toshinao Itani · 1 shared paper, 2024 · strength 0.13
  24. Kozo Ikuta · 1 shared paper, 2024 · strength 0.13
  25. Nobuhiro Hieda · 1 shared paper, 2024 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.